Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
/in International Publications, Newcastle Disease Virus /von 2008-02-15 / Biochim. Biophys. Acta 2008 Apr;1785(2):217-31Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7Dendritic cell vaccines in melanoma: from promise to proof?
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-34Immunisation with ’naïve‘ syngeneic dendritic cells protects mice from tumour challenge
/in Breast Cancer, International Publications /von 2008-02-05 / Br. J. Cancer 2008 Feb;98(4):784-91Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose?
/in International Publications, Soft Tissue Sarcoma /von 2008-02-01 / Oncologist 2008 Feb;13(2):175-86[Dendritic cells elicit cellular immune response by targeting to capture breast cancer cells]
/in Breast Cancer, International Publications /von 2008-02-01 / Zhonghua Zhong Liu Za Zhi 2008 Feb;30(2):107-11Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond
/in International Publications, Malignant Lymphoma /von 2008-02-01 / Am. J. Hematol. 2008 Feb;83(2):144-9Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2008-02-01 / Horm. Metab. Res. 2008 Feb;40(2):108-16Immunotherapy opportunities in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-57
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution